Progenity Presents Proof-of-Concept Data on Proprietary Ingestible Technologies for Diagnosis, Monitoring, and Treatment of Gastrointestinal Disorders

SAN DIEGO–(BUSINESS WIRE)–Progenity, Inc., a privately held biotechnology company developing proprietary precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, this week announced results from three studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive diseases through ingestible technologies. Proof-of-concept studies in both human and pre-clinical models showed Progenity?s ing